Drug Profile
Tumour lysate particle loaded dendritic cell vaccine - Elios Therapeutics
Alternative Names: TL + YCWP + DC; TL-YCWP-DC; TLPLDCLatest Information Update: 30 Sep 2022
Price :
$50
*
At a glance
- Originator Elios Therapeutics
- Developer Cancer Insight; Elios Therapeutics; Perseus
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma
- Phase I/II Ovarian cancer
- No development reported Solid tumours
Most Recent Events
- 11 May 2022 Elios Therapeutics completes a phase IIa trial in Malignant melanoma (Late-stage disease, Metastatic disease, Adjuvant therapy, Monotherapy) in USA (Intradermal) (NCT02301611)
- 05 Aug 2020 Long-term final efficacy data from a phase IIb trial in Malignant melanoma released by Elios Therapeutics
- 22 Jun 2020 Efficacy data from phase IIb trial in Malignant melanoma presented at 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)